RxDoctor Payments Data

John Morgan, MD

Neurology · Augusta, GANPI 1023127024

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $548,277 of the $714,678 with a category attached, or 76.7%. 43 manufacturers reported payments, led by Amneal Pharmaceuticals LLC at 38.4% of the total. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$714,678in general payments, 2019–2025

Across 962 payments — averaging $742.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$275K
  • Kyowa Kirin, Inc.$184K
  • Lilly USA, LLC$98K
  • Acadia Pharmaceuticals Inc$44K
  • Neurocrine Biosciences, Inc.$23K
  • Biogen$22K
  • plus $69K from 37 others
$594,127in research payments, 2019–2025

Across 104 payments — averaging $5712.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • UCB SA$200K
  • AbbVie$175K
  • Sunovion Pharmaceuticals Inc.$56K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$50K
  • Roche Diagnostics Operations, Inc.$31K
  • Eli Lilly$25K
  • plus $57K from 5 others

What the payments were for

  • Consulting fees$97,86414%
  • Speaking & faculty fees$548,27777%
  • Travel & lodging$42,7836%
  • Food & beverage$19,8973%
  • Education$5,8571%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714,678 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$81,863
Medicare patients
578
Services billed
981

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa14$29,641
MyrbetriqMirabegron13$11,294
Carbidopa-LevodopaCarbidopa/Levodopa204$9,853
Memantine Hcl229$9,509
Galantamine Hbr72$8,216
Rasagiline Mesylate30$5,436
Donepezil Hcl331$4,026
AmantadineAmantadine Hcl43$2,140
Pramipexole DihydrochloridePramipexole Di-Hcl60$1,930
Primidone39$1,124
Carbidopa-Levodopa ErCarbidopa/Levodopa15$1,013
Ropinirole Hcl32$998
Sertraline Hcl84$844
Propranolol Hcl38$783
Gabapentin31$610

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$274,761$29,64114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.

Other neurology in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →